Targeting p53-dependent stem cell loss for intestinal chemoprotection

Targeting of p53- and PUMA-dependent apoptosis protects intestinal stem cells, but not cancer cells, against chemotherapy. Safer without PUMA Gastrointestinal toxicity is a major cause of side effects from chemotherapy and radiation, which can greatly decrease the quality of life and limit the dosing of cancer treatments. Tumor suppressor p53 plays a major role in chemotherapy-induced intestinal cell death, but inhibiting p53 is not safe because a loss of p53 would worsen cancer growth. Instead, Leibowitz et al. showed that one can block only the detrimental function of p53 by inhibiting its downstream effector, PUMA. A small-molecule inhibitor of PUMA protected intestinal cells in mice and in human colon organoids but did not protect cancer cells, suggesting that this could be a viable strategy for intestinal protection in cancer patients. The gastrointestinal (GI) epithelium is the fastest renewing adult tissue and is maintained by tissue-specific stem cells. Treatment-induced GI side effects are a major dose-limiting factor for chemotherapy and abdominal radiotherapy and can decrease the quality of life in cancer patients and survivors. p53 is a key regulator of the DNA damage response, and its activation results in stimulus- and cell type–specific outcomes via distinct effectors. We demonstrate that p53-dependent PUMA induction mediates chemotherapy-induced intestinal injury in mice. Genetic ablation of Puma, but not of p53, protects against chemotherapy-induced lethal GI injury. Blocking chemotherapy-induced loss of LGR5+ stem cells by Puma KO or a small-molecule PUMA inhibitor (PUMAi) prevents perturbation of the stem cell niche, rapid activation of WNT and NOTCH signaling, and stem cell exhaustion during repeated exposures. PUMAi also protects human and mouse colonic organoids against chemotherapy-induced apoptosis and damage but does not protect cancer cells in vitro or in vivo. Therefore, targeting PUMA is a promising strategy for normal intestinal chemoprotection because it selectively blocks p53-dependent stem cell loss but leaves p53-dependent protective effects intact.

[1]  W. El-Deiry,et al.  Faculty Opinions recommendation of Targeting p53-dependent stem cell loss for intestinal chemoprotection. , 2018 .

[2]  Jian Yu,et al.  Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice. , 2016, The Journal of clinical investigation.

[3]  Toshiro Sato,et al.  Efficient genetic engineering of human intestinal organoids using electroporation , 2015, Nature Protocols.

[4]  Linheng Li,et al.  Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation , 2015, Scientific Reports.

[5]  M. Hauer-Jensen,et al.  Radiation enteropathy—pathogenesis, treatment and prevention , 2014, Nature Reviews Gastroenterology &Hepatology.

[6]  C. Taniguchi,et al.  PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal Toxicity via HIF2 , 2014, Science Translational Medicine.

[7]  G. Doherty,et al.  Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. , 2014, World journal of gastroenterology.

[8]  Jian Yu,et al.  Ionizing irradiation induces acute haematopoietic syndrome and gastrointestinal syndrome independently in mice , 2014, Nature Communications.

[9]  F. D. de Sauvage,et al.  Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration. , 2014, Cell stem cell.

[10]  Jian Yu,et al.  Role of Apoptosis in Colon Cancer Biology, Therapy, and Prevention , 2013, Current Colorectal Cancer Reports.

[11]  J. Geng,et al.  Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection , 2013, Nature.

[12]  Jian Yu,et al.  Intestinal stem cell injury and protection during cancer therapy. , 2013, Translational cancer research.

[13]  L. Zhang,et al.  ADAR1 is essential for intestinal homeostasis and stem cell maintenance , 2013, Cell Death and Disease.

[14]  Alexander van Oudenaarden,et al.  Identifying the stem cell of the intestinal crypt: strategies and pitfalls. , 2012, Cell stem cell.

[15]  Matthias Stelzner,et al.  A nomenclature for intestinal in vitro cultures. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[16]  M. Berbée,et al.  Novel drugs to ameliorate gastrointestinal normal tissue radiation toxicity in clinical practice: what is emerging from the laboratory? , 2012, Current opinion in supportive and palliative care.

[17]  P. Dempsey,et al.  Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells , 2012, Development.

[18]  Hans Clevers,et al.  Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.

[19]  Jian Yu,et al.  PUMA–mediated apoptosis drives chemical hepatocarcinogenesis in mice , 2011, Hepatology.

[20]  Jian Yu,et al.  p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. , 2011, Gastroenterology.

[21]  Jian Yu,et al.  PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. , 2011, The Journal of clinical investigation.

[22]  Jian Yu,et al.  Uncoupling p53 Functions in Radiation-Induced Intestinal Damage via PUMA and p21 , 2011, Molecular Cancer Research.

[23]  Ivet Bahar,et al.  Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. , 2011, Current topics in medicinal chemistry.

[24]  M. Wong,et al.  Characterization of the intestinal cancer stem cell marker CD166 in the human and mouse gastrointestinal tract. , 2010, Gastroenterology.

[25]  Jian Yu,et al.  Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis , 2010, Proceedings of the National Academy of Sciences.

[26]  G. Krumschnabel,et al.  Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. , 2010, Genes & development.

[27]  A. Strasser,et al.  Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. , 2010, Genes & development.

[28]  A. Gudkov,et al.  Pathologies associated with the p53 response. , 2010, Cold Spring Harbor perspectives in biology.

[29]  W. Voigt,et al.  Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management , 2010, Therapeutic advances in medical oncology.

[30]  Jian Yu,et al.  Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis , 2009, Oncogene.

[31]  S. Korsmeyer,et al.  p53 Controls Radiation-Induced Gastrointestinal Syndrome in Mice Independent of Apoptosis , 2009, Science.

[32]  Jian Yu,et al.  PUMA is directly activated by NF-κB and contributes to TNF-α-induced apoptosis , 2009, Cell Death and Differentiation.

[33]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[34]  Jian Yu,et al.  PUMA, a potent killer with or without p53 , 2008, Oncogene.

[35]  Jian Yu,et al.  Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. , 2008, Blood.

[36]  Jian Yu,et al.  PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. , 2008, Cell stem cell.

[37]  Jian Yu,et al.  Chemosensitization of head and neck cancer cells by PUMA , 2007, Molecular Cancer Therapeutics.

[38]  H. Clevers,et al.  Tracking down the stem cells of the intestine: strategies to identify adult stem cells. , 2007, Gastroenterology.

[39]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[40]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[41]  A. Prabowo,et al.  Role of p53 in irinotecan-induced intestinal cell death and mucosal damage , 2007, Anti-cancer drugs.

[42]  Jian Yu,et al.  p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia–reperfusion , 2006, Gut.

[43]  Peng Wang,et al.  PUMA Dissociates Bax and Bcl-XL to Induce Apoptosis in Colon Cancer Cells* , 2006, Journal of Biological Chemistry.

[44]  Jian Yu,et al.  PUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation , 2006, Clinical Cancer Research.

[45]  Jian Yu,et al.  The transcriptional targets of p53 in apoptosis control. , 2005, Biochemical and biophysical research communications.

[46]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[47]  J. Goldblum,et al.  Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice , 2004, Oncogene.

[48]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[49]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[50]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[52]  A. Cummins,et al.  Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans , 2000, Gut.

[53]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[54]  M Nomura,et al.  Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. , 1996, Cancer research.

[55]  P. Vrignaud,et al.  Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice , 1996, Anti-cancer drugs.

[56]  B. Calabretta,et al.  Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants , 1993, Clinical & Experimental Metastasis.

[57]  M. Iigo,et al.  Relationship between Development of Diarrhea and the Concentration of SN‐38, an Active Metabolite of CPT‐11, in the Intestine and the Blood Plasma of Athymic Mice Following Intraperitoneal Administration of CPT‐11 , 1993, Japanese journal of cancer research : Gann.

[58]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[59]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[60]  T. Tanaka,et al.  Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors. , 1987, Cancer research.

[61]  D. Tousoulis,et al.  The Role of Inflammation , 2018 .

[62]  Jian Yu,et al.  DNA Damage and Cellular Stress Responses Uncoupling p 53 Functions in Radiation-Induced Intestinal Damage via PUMA and p 21 , 2011 .